The arrival of Ozempic in India has sparked a significant discussion about diabetes treatment, but is it the miracle solution many perceive it to be? Novo Nordisk's Managing Director in India, Vikrant Shrotriya, recently discussed the launch of Ozempic (semaglutide) with NDTV, shedding light on its role in managing diabetes in a country grappling with over 100 million adults with type 2 diabetes. This injectable medication is making waves globally, partly due to its weight loss effects and celebrity endorsements. But, according to Novo Nordisk, its primary focus in India remains firmly rooted in diabetes care and responsible medical use.
So, why does Ozempic's introduction matter so much for India's diabetes problem?
Shrotriya explains that many existing diabetes treatments struggle to provide sustained blood sugar control and often lead to weight gain, which complicates long-term management. He believes Ozempic offers doctors an additional, more comprehensive option.
"Patients often don't achieve the HbA1c control they need, and if they do, it comes at the cost of weight gain," he stated. Semaglutide, he added, can reduce HbA1c levels by as much as 2.8% while also aiding in weight loss.
But here's where it gets controversial...
Ozempic is widely recognized for its weight loss capabilities. Has this overshadowed its primary medical purpose? Shrotriya acknowledges that misinformation has influenced public perception. He cautions that fear-driven narratives could deter patients who genuinely need the drug, while others might resort to self-medication based on social media trends.
"The correct approach is to consult a doctor, get a prescription, and obtain the medication from a legitimate pharmacy," he emphasized, stressing that Ozempic should only be taken under medical supervision.
What about the potential side effects?
Addressing safety concerns, Shrotriya acknowledges that all medications carry risks, but he believes Ozempic's benefits clearly outweigh them when used correctly. He points out that the drug has undergone extensive evaluation by regulatory bodies worldwide, including in India.
"These risks have been carefully studied. The benefit-risk balance is appropriate for treating type 2 diabetes," he said, urging patients to rely on medical advice rather than online information.
How is Novo Nordisk preventing misuse for cosmetic or off-label purposes?
The company strongly discourages self-medication and misuse. Shrotriya highlights the importance of patient education.
"We are emphasizing, please do not self-medicate," he said, adding that professional medical guidance should not be replaced by social media.
With Ozempic and Wegovy in its portfolio, is Novo Nordisk promoting medication over lifestyle changes?
The company insists that medication alone is insufficient. Shrotriya stresses that diet, exercise, and lifestyle changes are crucial in managing metabolic disorders like diabetes and obesity.
"This is not a quick fix. It's not a panacea," he stated, describing diabetes as "a chronic and progressive condition influenced by genetics, environment, and lifestyle. Medication must be part of an integrated approach that includes nutrition, physical activity, and regular monitoring."
Celebrities have called it transformational. Is Ozempic becoming a 'miracle drug'?
Shrotriya firmly rejects this characterization. "There are no miracles in science. This is today's science. Ozempic is a powerful therapy; it should not be mistaken for a cure-all solution," he said.
How does Novo Nordisk view competition from Eli Lilly's Mounjaro in India?
Instead of focusing on market rivalry, Shrotriya frames the challenge as a public health issue. "The real competition is the disease," he said, noting that 250 million Indians are affected by obesity and over 100 million have diabetes. He describes the launch of semaglutide as a potential "watershed moment" with the capacity to "bend the curve" of diabetes and obesity if used responsibly.
How is Ozempic priced for the Indian market, and is it affordable?
Ozempic has been launched at around Rs 2,200 per week, significantly lower than in markets like the US. Shrotriya says the company adopted a "tailored Indian pricing" approach after consulting doctors, patients, and market data.
"Innovation without access does not make sense. The goal is to balance commercial sustainability with wider patient access." However, he acknowledges that affordability alone won't ensure impact, pointing to gaps in awareness and diagnosis, especially outside urban centers.
What myths surrounding Ozempic and similar drugs need to be addressed?
One major misconception, Shrotriya points out, is that Ozempic allows patients to disregard lifestyle discipline.
"You cannot do anything you want and expect diabetes control," he said. Addressing fears about muscle loss or facial changes, he explained that muscle loss can occur with any significant weight reduction and must be countered through strength training and balanced nutrition. Claims linking the drug to eye damage or pancreatitis, he said, are rare and not supported by evidence of a direct causal relationship.
Finally, is Ozempic a medicine or a wellness product?
"It is a medicine," Shrotriya concluded.
What are your thoughts? Do you think the benefits of Ozempic outweigh the risks? Share your opinions and experiences in the comments below!
Disclaimer: This content provides generic information only and is not a substitute for professional medical advice. Always consult with a healthcare provider for any health concerns.
